Catalog No.
DHB88502
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a, kappa
Target
Properdin factor B, Complement factor B, GBG, Glycine-rich beta glycoprotein, BFD, C3/C5 convertase, CFB, PBF2, BF
Concentration
2.63 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P00751
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.94mM Citric acid, 16.7mM Trisodium citrate dihydrate, 6.2% sucrose, pH 6.5, 0.01% Tween 80.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAR-443809
Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis., PMID:40504283
Effects of C3aR activated mast cells in eosinophilic esophagitis., PMID:40502038
Efficacy and safety of tafolecimab a new PCSK9 inhibitor in patients with hyperlipidemia: a systematic review and meta-analysis of randomized controlled trials., PMID:40478366
Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study., PMID:40450840
Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial., PMID:40441802
TLR7 responses in glomerular macrophages accelerate the progression of glomerulonephritis in NZBWF1 mice., PMID:40401698
Reference intervals for serum immunoglobulin A, G, and M in a Danish paediatric population-based cohort., PMID:40174761
A non-invasive model for diagnosis of primary Sjogren's disease based on salivary biomarkers, serum autoantibodies, and Schirmer's test., PMID:39695856
Quality of life and clinical gout assessments during pegloticase with and without methotrexate co-therapy: MIRROR randomized controlled trial exploratory findings., PMID:39678124
Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study., PMID:39520835
Immune Indicator Changes in Hepatocellular Carcinoma Undergoing TACE Plus ICIs and Anti-VEGF Antibodies/TKIs: A Prognostic Biomarker Analysis., PMID:39465041
Efficacy, safety and tolerability of GSK3858279, an anti-CCL17 monoclonal antibody and analgesic, in healthy volunteers and patients with knee osteoarthritis pain: a phase I, randomised, double-blind, placebo-controlled, proof-of-mechanism and proof-of-concept study., PMID:39419538
Prediction of Cardiac ATTR Depletion by NI006 (ALXN2220) Using Mechanistic PK/PD Modeling., PMID:39410666
A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification., PMID:39383863
Long term safety and efficacy of ligelizumab in the treatment of Japanese patients with chronic spontaneous urticaria., PMID:39327219
Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records., PMID:39012863
A comparison of different intensified upstream processes highlighting the advantage of WuXi Biologics' Ultra-high Productivity platform (WuXiUPTM) in improved product quality and purification yield., PMID:38980213
Time-course and dose-effect of omalizumab in treating chronic idiopathic urticaria/chronic spontaneous urticaria., PMID:38967658
Safety and Immunogenicity of a 4-Component Generalized Modules for Membrane Antigens Shigella Vaccine in Healthy European Adults: Randomized, Phase 1/2 Study., PMID:38853614
Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study., PMID:38729747
Evaluating the real-world effectiveness of belimumab in patients with SLE using SLE-related laboratory values and rheumatoid arthritis-derived disease activity measures: RAPID3, swollen joint count and tender joint count., PMID:38575172
Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head-to-Head Randomized Phase IIIb Study., PMID:38556921
Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study., PMID:38477751
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C)., PMID:38379107
INDIVIDUAL ARTICLE: Sarecycline Improves Acne Severity, Symptoms, and Psychosocial Burden in Non-nodular Acne Vulgaris: PROSES Study., PMID:38306152
[Comparative characteristics of the complement system in patients with C3-glomerulopathy and atypical hemolytic uremic syndrome of chronic course who suffered an acute episode of thrombotic microangiopathy]., PMID:38158966
Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab., PMID:38151388
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials., PMID:38008109
Complement-mediated thrombotic microangiopathy treated with anticomplement protein 5 therapy, a retrospective study., PMID:37984551
Complement alternative pathway determines disease susceptibility and severity in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis., PMID:37923132
Atypical hemolytic uremic syndrome: genetically-based insights into pathogenesis through an analysis of the complement regulator CD46., PMID:39949759
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study., PMID:37318750
Alternative Complement Pathway Inhibition by Lampalizumab: Analysis of Data From Chroma and Spectri Phase III Clinical Trials., PMID:37228694
TMA in Kidney Transplantation., PMID:36944606
Risk control of host cell proteins in one therapeutic antibody produced by concentrated fed-batch (CFB) mode., PMID:36874608
CFH-CFHR1 hybrid genes in two cases of atypical hemolytic uremic syndrome., PMID:36755127
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis., PMID:36644237
Variants in complement genes are uncommon in patients with anti-factor H autoantibody-associated atypical hemolytic uremic syndrome., PMID:36622444
Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial., PMID:36575505
Lentiviral Gene Therapy for Artemis-Deficient SCID., PMID:36546626
A Phase I, Single Ascending Dose Study of GEM103 (Recombinant Human Complement Factor H) in Patients with Geographic Atrophy., PMID:36249705
Potential participation of CTRP6, a complement regulator, in the pathology of age related macular degeneration., PMID:35397057
Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study., PMID:35377447
Systematic review of atypical hemolytic uremic syndrome biomarkers., PMID:35118546
Blockade of the Terminal Complement Cascade Using Ravulizumab in a Pediatric Patient With Anti-complement Factor H Autoantibody-Associated aHUS: A Case Report and Literature Review., PMID:34912617
Serum complement factor B is associated with disease activity and progression of idiopathic membranous nephropathy concomitant with IgA nephropathy., PMID:34585312
Sodium Iodate-Induced Degeneration Results in Local Complement Changes and Inflammatory Processes in Murine Retina., PMID:34502128
Multiplex gene analysis reveals T-cell and antibody-mediated rejection-specific upregulation of complement in renal transplants., PMID:34326417
Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus., PMID:33558436
For research use only. Not for human or drug use.
